We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
101
PUT
Celldex Therapeutics
CLDX
$2.79B
$4.44M 0.16%
117
+14
+14% +$5.56K
ZGNX
102
CALL
DELISTED
Zogenix, Inc.
ZGNX
$4.28M 0.16%
3,186
+655
+26% +$8.03K
CDTX
103
DELISTED
Cidara Therapeutics
CDTX
$4.14M 0.15%
+14,749
New +$4.54M
FNCX
104
DELISTED
Function(x) Inc.
FNCX
$4.05M 0.15%
+98,846
New +$4.53M
VXX
105
CALL
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
$4.03M 0.15%
+125
New +$40.7K
LAB icon
106
Standard BioTools
LAB
$311M
$4M 0.15%
+165,385
New +$5.22M
MBLY
107
DELISTED
Mobileye N.V.
MBLY
$3.93M 0.14%
73,832
-152,248
-67% -$7.21M
IOVA icon
108
Iovance Biotherapeutics
IOVA
$2.1B
$3.92M 0.14%
427,244
+52,010
+14% +$580K
RGLS
109
DELISTED
Regulus Therapeutics
RGLS
$3.78M 0.14%
2,872
+698
+32% +$1.13M
AGIO icon
110
PUT
Agios Pharmaceuticals
AGIO
$2.14B
$3.73M 0.14%
336
+274
+442% +$29.5K
ITCI
111
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.65M 0.13%
+1,141
New +$28.9K
ABUS icon
112
Arbutus Biopharma
ABUS
$871M
$3.62M 0.13%
305,351
+134,530
+79% +$2.05M
OPK icon
113
Opko Health
OPK
$1.23B
$3.59M 0.13%
223,126
+45,575
+26% +$709K
SGMO
114
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.59M 0.13%
323,390
+63,649
+25% +$821K
CHL
115
CALL
DELISTED
China Mobile Limited
CHL
$3.58M 0.13%
+559
New +$38.2K
ZSPH
116
PUT
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$3.35M 0.12%
+640
New +$31.5K
QRHC icon
117
Quest Resource Holding
QRHC
$28.3M
$3.31M 0.12%
383,524
+6,218
+2% +$59.1K
PBYI icon
118
PUT
Puma Biotechnology
PBYI
$406M
$3.3M 0.12%
283
-365
-56% -$66.1K
ESPR
119
PUT
DELISTED
Esperion Therapeutics
ESPR
$3.26M 0.12%
+399
New +$39.1K
NWBO
120
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$3.26M 0.12%
+328,400
New +$2.88M
ADVM
121
DELISTED
Adverum Biotechnologies
ADVM
$3.21M 0.12%
19,780
+14,286
+260% +$4.82M
VXX
122
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
$3.18M 0.12%
+9,875
New +$3.21M
THMO
123
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
$3.15M 0.12%
412
-32
-7% -$251K
PSTV icon
124
Plus Therapeutics
PSTV
$25.9M
$2.99M 0.11%
+2
New +$4.58M
ENDP
125
DELISTED
Endo International plc
ENDP
$2.98M 0.11%
37,358
+11,367
+44% +$982K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.